LILETTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090186 | MEDICINES360 | Methods for using intrauterine systems and IUD insertion devices |
Oct, 2033
(9 years from now) | |
| US10028858 | MEDICINES360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
Mar, 2034
(9 years from now) | |
| US11571328 | MEDICINES360 | IUD insertion devices |
Sep, 2040
(16 years from now) | |
Liletta is owned by Medicines360.
Liletta contains Levonorgestrel.
Liletta has a total of 3 drug patents out of which 0 drug patents have expired.
Liletta was authorised for market use on 26 February, 2015.
Liletta is available in intrauterine device;intrauterine dosage forms.
Liletta can be used as a method for prevention of pregnancy.
The generics of Liletta are possible to be released after 07 September, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-917) | Jun 29, 2026 |
| New Product(NP) | Feb 26, 2018 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
More Information on Dosage
LILETTA family patents
